Cyclacel Pharmaceuticals (CYCC): Stock Quotes

The market dynamics of Cyclacel Pharmaceuticals (CYCC) securities on the GURU.Markets platform are based on the use of AI and robotics to automate the selection of drug formulas. Cyclacel Pharmaceuticals creates agents that block the division of tumor cells, making the therapy universal for various types of cancer. The current indicator stands at 6.33, while the business is actively spending its available capital to conduct clinical trials under budget constraints.

CYCC - Cyclacel, Inc. Stock Quotes over the range 07/04/2022 - 09/12/2025

CYCC (Cyclacel Pharmaceuticals Inc.): analytical breakdowns and indicator data

- stock quotes and analyst forecast:

Stock Price Cyclacel Pharmaceuticals, Inc.|CYCC - Consensus Target

- stock exchange capitalization data:

Market Valuation Cyclacel Pharmaceuticals, Inc.|CYCC - Total Enterprise Value

- issuer book value statistics:

Book Value per Share Cyclacel|CYCC - Company Net Assets|Market Capitalization to Book Value Ratio cyclacel.com|CYCC - Cumulative Company Assets

- debt level and financial liquidity data:

Total Debt to Capital Cyclacel Pharmaceuticals|CYCC - Long-Term Indebtedness to Equity|Short-Term Debt to Capital Cyclacel Pharmaceuticals, Inc.|CYCC - Company Cumulative Debt|Debt to Book Capitalization Ratio Cyclacel Pharmaceuticals|CYCC - Company Long-Term Indebtedness|Company Short-Term Debts Cyclacel|Quick Liquidity cyclacel.com

- earnings and market ratios statistics:

CYCC - Final Profit|Projected Future Earnings Cyclacel Pharmaceuticals|CYCC - P/E Multiple|Future Price to Earnings Cyclacel Pharmaceuticals Inc.|CYCC - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Cyclacel|CYCC - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Cyclacel|CYCC - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months cyclacel.com|CYCC - Earnings per share growth this year|Earnings growth forecast for next year Cyclacel Pharmaceuticals

- total revenue and sales volume data:

CYCC - Company Sales|Company Projected Revenue Cyclacel, Inc.|CYCC - Price to Sales|Price-to-Projected Revenue Ratio Cyclacel, Inc.|CYCC - Sales Growth YoY (Last Twelve Months)

Analysis of all company metrics:CYCC Cyclacel Pharmaceuticals Inc.

Investors in Cyclacel Pharmaceuticals (CYCC) must evaluate the company's market position through the lens of developing targeted inhibitors for the therapy of solid tumors. The current value of 6.33 reflects the aggregate asset capitalization and market consensus regarding the potential of clinical trials, while the price chart allows for the differentiation of organic business growth from speculative volatility, determining the long-term value stability of the issuer.

Who Cyclacel Pharmaceuticals competes with